Fat Loss
Tesamorelin
The Visceral Fat Protocol
The only FDA-approved peptide for visceral fat reduction. Pulsatile growth hormone release, targeted deep-organ fat loss, and a 26-week clinical evidence base. Reconstitution, daily dosing, blood monitoring, and realistic timelines.
FDA Status
Approved 2010 as Egrifta®
Primary Effect
Targeted visceral fat reduction
Clinical Result
15.2% mean visceral fat reduction (Phase III)
Dose
2 mg daily · Before bed
Who this guide is for.
Those with stubborn visceral (belly) fat who need a clinically proven, FDA-approved approach with measurable results at 6–8 weeks.
Preview
See what you get.
Real pages from this guide. Clear, structured, and actionable from page one.
Quick Start Overview
Full Protocol
Unlock with purchase
Dosing & Safety
Unlock with purchase
What's Inside
32 pages. 12 chapters.
Not a blog post. A protocol.
Evidence-Based
Every dosing recommendation is grounded in clinical research and practitioner protocols — not forum anecdotes.
Action-Ready
Not theory — a step-by-step operating manual from first reconstitution to cycle end.
Safety-First
Full side effect profiles, contraindications, and monitoring requirements. No information withheld.
Get the Tesamorelin guide.
32 pages. 12 chapters. Everything from reconstitution to cycle end - in one PDF.